Suggested remit: To appraise the clinical and cost effectiveness of atogepant within its marketing authorisation for treating migraine.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6615
Provisional Schedule
- Expected publication:
- 09 July 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- AbbVie (atogepant)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Migraine Trust
- Professional groups
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Associated public health groups
- None
- Comparator companies
- Pfizer (rimegepant) (confidentiality agreement signed, participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 January 2026 | Invitation to participate |
| 23 October 2025 - 20 November 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 23 October 2025 | In progress. Scoping commenced. |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual